Community-Based Screening for Chronic Kidney Disease
Public ClinicalTrials.gov record NCT07747363. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Chronic Kidney Disease (CKD) incubates for years before kidney function declines to such low levels that patients develop symptoms and present for medical evaluation. The earlier in its course that CKD is identified, the more likely that medical care can slow or stop further worsening toward complete loss of kidney function, or end-stage kidney disease (ESKD). Individuals living in low income, largely minority communities are at greater risk for CKD than those in wealthier, non-minority communities but have historic mistrust of research. This project will conduct screening for high levels of a urine protein called albumin, indicating underlying CKD, in churches known to have the trust of communities, to identify asymptomatic individuals with CKD to be offered referral for kidney-protective medical care. Upon completion, this project will determine if individuals so identified with CKD will 1) accept referral for CKD care; 2) remain in care for at least 12 months; and 3) achieve a reduction in urine albumin levels, indicating CKD improvement. As such, this project will determine the value of community-based screening to reduce CKD prevalence.
Study identification
- NCT ID
- NCT07747363
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 145 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 20, 2006
- Primary completion
- Dec 14, 2011
- Completion
- May 9, 2024
- Last update posted
- Aug 5, 2026
2006 – 2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dell Medical School - The University of Texas at Austin | Austin | Texas | 78712 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07747363, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 5, 2026 · Synced Sep 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07747363 live on ClinicalTrials.gov.